MODEM Dementia Evidence Database

Vitamins B₁₂, B₆, and folic acid for cognition in older men

Ford, A. H., Flicker, L., Alfonso, H., Thomas, J., Clarnette, R., Martins, R., Almeida, O. P.

[Correction Notice: An erratum for this article was reported in Vol 77(8) of Neurology (see record [rid]2011-21984-022[/rid]). In the original article, the daily dose of vitamin B12 used in the trial was reported as 400 μg, but it should have been 500 μg.] Objective: To investigate whether supplementing older men with vitamins B12, B6, and […]

Duration of antihypertensive drug use and risk of dementia: A prospective cohort study

Haag, M. D. M., Hofman, A., Koudstaal, P. J., Breteler, M. M. B., Stricker, B. H. C.

Background: The evidence from prospective observational research for a protective effect of antihypertensive drug use on the risk of dementia is far from uniform. Duration of follow-up was limited and relied mainly on baseline drug exposure data without information on duration of use. We investigated the association between the duration of antihypertensive use and risk […]

Treatment of vascular risk factors is associated with slower decline in Alzheimer disease

Deschaintre, Yan, Richard, Florence, Leys, Didier, Pasquier, Florence

Background: There is growing evidence that vascular risk factors (VRF) contribute to cognitive decline. Whether their treatment can slow down the progression of Alzheimer disease (AD) remains unsettled. The aim of this observational study was to evaluate whether the treatment of VRF is associated with a slower cognitive decline in patients who have AD without […]

Use of anticholinergics and the risk of cognitive impairment in an African American population

Campbell, N. L., Boustani, M. A., Lane, K. A., Gao, S., Hendrie, H., Khan, B. A., Murrell, J. R., Unverzagt, F. W., Hake, A., Smith-Gamble, V., Hall, K.

Background: Anticholinergic properties of certain medications often go unrecognized, and are frequently used by the elderly population. Few studies have yet defined the long-term impact of these medications on the incidence of cognitive impairment. Methods: We report a 6-year longitudinal, observational study, evaluating 1,652 community-dwelling African American subjects over the age of 70 years who […]

Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes

Objectives: Our objective was to compare long-term outcomes of deep brain stimulation (DBS) of the globus pallidus interna (GPi) and subthalamic nucleus (STN) for patients with Parkinson disease (PD) in a multicenter randomized controlled trial.; Methods: Patients randomly assigned to GPi (n = 89) or STN DBS (n = 70) were followed for 36 months. […]

Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial

Newhouse, P., Kellar, K., Aisen, P., White, H., Wesnes, K., Coderre, E., Pfaff, A., Wilkins, H., Howard, D., Levin, E. D.

Objective: To preliminarily assess the safety and efficacy of transdermal nicotine therapy on cognitive performance and clinical status in subjects with mild cognitive impairment (MCI).; Methods: Nonsmoking subjects with amnestic MCI were randomized to transdermal nicotine (15 mg per day or placebo) for 6 months. Primary outcome variables were attentional improvement assessed with Connors Continuous […]

Increased CSF APPs-α levels in patients with Alzheimer disease treated with acitretin

Endres, Kristina, Fahrenholz, Falk, Lotz, Johannes, Hiemke, Christoph, Teipel, Stefan, Lieb, Klaus, Tüscher, Oliver, Fellgiebel, Andreas

Objective: We investigated induction of α-secretase A disintegrin and metalloprotease 10 (ADAM10) by the synthetic retinoid acitretin (Neotigason; Actavis, München-Riem, Germany) in patients with mild to moderate Alzheimer disease (AD) via measurement of CSF content of α-secretase-derived amyloid precursor protein (APPs-α).; Methods: Twenty-one patients clinically diagnosed with mild to moderate AD received acitretin (30 mg […]

Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease

Chen, Y., Wolk, D. A., Reddin, J. S., Korczykowski, M., Martinez, P. M., Musiek, E. S., Newberg, A. B., Julin, P., Arnold, S. E., Greenberg, J. H., Detre, J. A.

Objective: We compared the ability of arterial spin labeling (ASL), an MRI method that measures cerebral blood flow (CBF), to that of FDG-PET in distinguishing patients with Alzheimer disease (AD) from healthy, age-matched controls.; Methods: Fifteen patients with AD (mean age 72 ± 6 years, Mini-Mental State Examination score [MMSE] 20 ± 6) and 19 […]

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease

Sano, M., Bell, K. L., Galasko, D., Galvin, J. E., Thomas, R. G., van Dyck, C. H., Aisen, P. S.

Background: Lowering cholesterol is associated with reduced CNS amyloid deposition and increased dietary cholesterol increases amyloid accumulation in animal studies. Epidemiologic data suggest that use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) may decrease the risk of Alzheimer disease (AD) and a single-site trial suggested possible benefit in cognition with statin treatment in AD, […]

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

Salloway, S., Sperling, R., Keren, R., Porsteinsson, A. P., van Dyck, C. H., Tariot, P. N., Gilman, S., Arnold, D., Abushakra, S., Hernandez, C., Crans, G., Liang, E., Quinn, G., Bairu, M., Pastrak, A., Cedarbaum, J. M.

Objective: This randomized, double-blind, placebo-controlled, dose-ranging phase 2 study explored safety, efficacy, and biomarker effects of ELND005 (an oral amyloid anti-aggregation agent) in mild to moderate Alzheimer disease (AD).; Methods: A total of 353 patients were randomized to ELND005 (250, 1,000, or 2,000 mg) or placebo twice daily for 78 weeks. Coprimary endpoints were the […]

This database contains 30 abstracts archived under the term: "Neurology"

This database contains 30 studies, archived under the term: "Neurology"